C. J. Schmidt

发表

Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists

Brooke M. Roberts, Stacy A. Castner, Graham V. Williams, 2010, Psychopharmacology.

Gas-Liquid Chromatographic Isolation of Cytokinins from Natural Sources: 6-(3-Methyl-2-butenylamino) purine from Agrobacterium Tumefaciens.

C. J. Schmidt, C. Upper, J. Helgeson, 1970, Plant physiology.

Phosphodiesterases in the CNS: targets for drug development

F. Menniti, C. J. Schmidt, W. S. Faraci, 2006, Nature Reviews Drug Discovery.

Immunohistochemical localization of PDE10A in the rat brain

Jerry Lanfear, J. Culp, F. Menniti, 2003, Brain Research.

Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species

Daniel Morton, F. Menniti, D. Stephenson, 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Studies on the mechanism of tolerance to methamphetamine

C. J. Schmidt, G. Hanson, J. Gibb, 1985, Brain Research.

PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?

F. Menniti, C. J. Schmidt, T. Chappie, 2021, Frontiers in Neuroscience.

Role of dopamine in the neurotoxic effects of methamphetamine.

C. J. Schmidt, G. Hanson, J. Gibb, 1985, The Journal of pharmacology and experimental therapeutics.

Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site.

F. Salituro, B. Harrison, C. J. Schmidt, 1990, Molecular pharmacology.

The discovery and characterization of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor potentiator N-{(3S,4S)-4-[4-(5-cyano-2-thienyl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide (PF-04958242).

J. Pandit, R. Hurst, M. Hajós, 2015, Journal of medicinal chemistry.

Duplicated heavy metal control sequences of the mouse metallothionein-I gene.

D. Hamer, C. J. Schmidt, B. Felber, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574

R. Hurst, F. Menniti, M. Hajós, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction

Brooke M. Roberts, Graham V. Williams, F. Menniti, 2010, Behavioural Brain Research.

Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.

C. J. Schmidt, V. L. Taylor, Vicki L. Taylor, 1988, European journal of pharmacology.

Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine.

C. J. Schmidt, V. L. Taylor, C. K. Black, 1990, European journal of pharmacology.

Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.

W. Lovenberg, C. J. Schmidt, L. Wu, 1986, European journal of pharmacology.

In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain.

W. Lovenberg, C. J. Schmidt, J. A. Levin, 1987, Biochemical pharmacology.

Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs.

C. J. Schmidt, 1987, European journal of pharmacology.

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat

C. J. Schmidt, L. Matsuda, G. Hanson, 1986, Neuropharmacology.

Seed production in nodding and slender winged thistles by nodding thistle receptacle weevil

C. J. Schmidt, D. Kelly, K. McCallum, 1990 .

The isozyme selective phosphodiesterase-4 inhibitor, ABI-4, attenuates the effects of lipopolysaccharide in human cells and rodent models of peripheral and CNS inflammation

C. J. Schmidt, Z. Hughes, Ashley N. Hanks, 2017, Brain, Behavior, and Immunity.

Cell specificity and an effect of ras on human metallothionein gene expression.

D. Hamer, C. J. Schmidt, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Suppression of interleukin-1 beta and LDL scavenger receptor expression in macrophages by a selective protein kinase C inhibitor.

C. J. Schmidt, A. Akeson, C. Woods, 1991, Journal of lipid research.

In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine.

C. J. Schmidt, L. Matsuda, J. Gibb, 1984, European journal of pharmacology.

Effects of methamphetamine on central monoaminergic systems in normal and ascorbic acid-deficient guinea pigs.

C. J. Schmidt, L. Matsuda, G. Hanson, 1988, Biochemical pharmacology.

G. Stoner, C. J. Schmidt, M. Morse, 1993, Cancer letters.

Comparison of Neurotensin Responses to MDL 100,907, a Selective 5HT2A Antagonist, with Clozapine and Haloperidol

C. J. Schmidt, G. Hanson, J. Gibb, 1997, Brain Research Bulletin.

Radical Trapping and Inhibition of Iron‐Dependent CNS Damage by Cyclic Nitrone Spin Traps

C. J. Schmidt, Craig E. Thomas, D. Ohlweiler, 1997, Journal of neurochemistry.

Dopamine-mediated increases in nigral substance P-like immunoreactivity.

C. J. Schmidt, G. Hanson, J. Gibb, 1985, Biochemical pharmacology.

Cloning and sequence analysis of two monkey metallothionein cDNAs.

D. Hamer, C. J. Schmidt, 1983, Gene.

Chromosomal location of human metallothionein genes: implications for Menkes' disease.

D. Hamer, O. Mcbride, C. J. Schmidt, 1984, Science.

Structure and expression of two human metallothionein-I isoform genes and a related pseudogene.

D. Hamer, C. J. Schmidt, M. Jubier, 1985, The Journal of biological chemistry.

MDL 100,907: A Selective 5‐HT2A Receptor Antagonist for the Treatment of Schizophrenia

J. Kehne, C. J. Schmidt, A. Carr, 1997 .

Time-resolved fluorescence of the two tryptophans in horse liver alcohol dehydrogenase.

C. J. Schmidt, L. Brand, J. Ross, 1981, Biochemistry.

THE ROLE OF THE MONOAMINERGIC UPTAKE SYSTEMS IN THE NEUROCHEM1CAL RESPONSE

C. J. Schmidt, G. Hanson, D. N. Franz, 2012 .

Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid.

C. J. Schmidt, J. Gibb, 1985, European journal of pharmacology.

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating

P. Seymour, C. J. Schmidt, V. Risbrough, 2014, Psychopharmacology.

Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.

C. J. Schmidt, V. L. Taylor, C. K. Black, 1990, The Journal of pharmacology and experimental therapeutics.

Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.

C. J. Schmidt, V. L. Taylor, 1990, European journal of pharmacology.

Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine.

C. J. Schmidt, V. L. Taylor, 1987, Biochemical pharmacology.

Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade.

C. J. Schmidt, G. Fadayel, 1996, The Journal of pharmacology and experimental therapeutics.

Identification of Cytokinins by Gas-Liquid Chromatography and Gas-Liquid Chromatography-Mass Spectrometry

C. J. Schmidt, C. Upper, J. Helgeson, 1972 .

Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.

K. Fennell, J. Pandit, F. Menniti, 2011, Journal of medicinal chemistry.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Spiros Liras, Anne W. Schmidt, J. Pandit, 2009, Journal of medicinal chemistry.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

F. Menniti, F. Nelson, C. Proulx-Lafrance, 2012, Journal of medicinal chemistry.

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Spiros Liras, Meihua Tu, J. Pandit, 2007, Journal of medicinal chemistry.

Induction of ornithine decarboxylase, RNA, and protein synthesis in macrophage cell lines stimulated by immunoadjuvants

C. J. Schmidt, W. Nichols, F. H. Prosser, 1984, Journal of cellular physiology.

Ascorbic acid-deficient condition alters central effects of methamphetamine

C. J. Schmidt, L. Matsuda, G. Hanson, 1987, Brain Research.

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

F. Menniti, C. J. Schmidt, J. Humphrey, 2007, Current opinion in investigational drugs.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function

F. Menniti, J. Siuciak, J. Stock, 2006, Neuropharmacology.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis

F. Menniti, J. Siuciak, C. J. Schmidt, 2006, Neuropharmacology.

MDL 27,032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone], an active site-directed inhibitor of protein kinase C and cyclic AMP-dependent protein kinase that relaxes vascular smooth muscle.

H. Cheng, C. J. Schmidt, P. Robinson, 1990, Journal of Pharmacology and Experimental Therapeutics.

Chemoproteomics demonstrates target engagement and exquisite selectivity of the clinical phosphodiesterase 10A inhibitor MP-10 in its native environment.

N. Brandon, P. Verhoest, C. J. Schmidt, 2014, ACS chemical biology.

Lack of evidence supporting a role for dopamine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.

W. Lovenberg, C. J. Schmidt, E. Bruckwick, 1985, European journal of pharmacology.

In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat

W. Lovenberg, C. J. Schmidt, 1985, Neuroscience Letters.

Studies on the mechanism of p-chloroamphetamine neurotoxicity.

D E Nichols, C. J. Schmidt, C J Schmidt, 1996, Biochemical pharmacology.

5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats

J. Kehne, C. J. Schmidt, V. L. Taylor, 1996, Psychopharmacology.

5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.

C. J. Schmidt, G M Fadayel, C K Sullivan, 1992, European journal of pharmacology.

The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine.

C. J. Schmidt, T. Humphreys, S. Sorensen, 1992, European journal of pharmacology.

L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.

C. J. Schmidt, V. L. Taylor, C. K. Black, 1991, European journal of pharmacology.

Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.

C. J. Schmidt, C J Schmidt, 1987, The Journal of pharmacology and experimental therapeutics.

Gas-Liquid Chromatographic Isolation of Cytokinins from Natural Sources

C. J. Schmidt, J. Helgeson, J. Kemp, 2022 .

Pharmacological Manipulation of Cyclic Nucleotide Phosphodiesterase Signaling for The Treatment of Neurological and Psychiatric Disorders In The Brain

F. Menniti, C. J. Schmidt, N. Plath, 2014 .

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

J. Kehne, C. J. Schmidt, M. Palfreyman, 2005, Psychopharmacology.

Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene.

R. Andrade, J. Granneman, S. Burchett, 1998, Molecular pharmacology.

The role of 5-HT2A receptors in antipsychotic activity.

J. Kehne, C. J. Schmidt, M. Palfreyman, 1995, Life sciences.

PDE10A: A Striatum-Enriched, Dual-Substrate Phosphodiesterase

F. Menniti, C. J. Schmidt, C. Strick, 2006 .

Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist.

J. Kehne, F. Salituro, B. Harrison, 1997, European journal of pharmacology.

The putative 5-HT3 agonist phenylbiguanide induces carrier-mediated release of [3H]dopamine.

C. J. Schmidt, C. K. Black, C. Black, 1989, European journal of pharmacology.

Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF).

F. Tingley, C. J. Schmidt, E. Groeber, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Strychnine‐Sensitive, Glycine‐Induced Release of [3H]Norepinephrine from Rat Hippocampal Slices

C. J. Schmidt, V. L. Taylor, 1990, Journal of neurochemistry.

Neurochemical Effects of Methylenedioxymethamphetamine in the Rat: Acute Versus Long-Term Changes

C. J. Schmidt, V. L. Taylor, 1990 .

Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: Effects of citalopram and chlorimipramine

C. J. Schmidt, J. Gibb, 1985, Neurochemical Research.

Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington's Disease

C. J. Schmidt, M. Kuhn, S. Bove, 2011, Journal of Pharmacology and Experimental Therapeutics.

5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa.

C. J. Schmidt, V. L. Taylor, T. Nieduzak, 1991, The Journal of pharmacology and experimental therapeutics.

Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors

C. J. Schmidt, V. L. Taylor, C. K. Black, 1990, Brain Research.

Response of mesolimbic substance P systems to methamphetamine treatment.

C. J. Schmidt, G. Hanson, J. Gibb, 1986, European journal of pharmacology.

Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment.

C. J. Schmidt, G. Hanson, J. Gibb, 1984, The Journal of pharmacology and experimental therapeutics.

Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

Laura McDowell, Scot Mente, Mihaly Hajos, 2017, Journal of medicinal chemistry.

Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo

Anne W. Schmidt, F. Menniti, M. Hajós, 2012, Journal of Pharmacology and Experimental Therapeutics.

Phosphodiesterase inhibitors as potential cognition enhancing agents.

C. J. Schmidt, 2010, Current topics in medicinal chemistry.

Glycine transporter inhibition reverses ketamine-induced working memory deficits

Brooke M. Roberts, Graham V. Williams, P. Seymour, 2010, Neuroreport.

Myosin I heavy-chain genes of Acanthamoeba castellanii: cloning of a second gene and evidence for the existence of a third isoform.

C. J. Schmidt, J. Hammer, G. Jung, 1989, Gene.

Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats.

J. Kehne, C. J. Schmidt, V. L. Taylor, 1992, The Journal of pharmacology and experimental therapeutics.

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

A. West, F. Menniti, S. Threlfell, 2009, Journal of Pharmacology and Experimental Therapeutics.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background

J. Siuciak, C. J. Schmidt, D. Chapin, 2008, Neuropharmacology.

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A

F. Menniti, C. J. Schmidt, T. Seeger, 2010, Neuropharmacology.

Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone

A. Carlsson, C. J. Schmidt, P. Martin, 1998, Journal of Neural Transmission.

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

J. Kehne, C. J. Schmidt, T. Humphreys, 1993, The Journal of pharmacology and experimental therapeutics.

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models

Christer Halldin, Mei Kwan, Andrea Varrone, 2016, Neuron.

Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications

F. Menniti, C. J. Schmidt, S. Papa, 2014, Neuropharmacology.

Facilitation of Corticostriatal Transmission following Pharmacological Inhibition of Striatal Phosphodiesterase 10A: Role of Nitric Oxide-Soluble Guanylyl Cyclase-cGMP Signaling Pathways

A. West, S. Threlfell, C. J. Schmidt, 2015, The Journal of Neuroscience.

Selective Brain Penetrant PDE 9 A Inhibitor for the Treatment of Cognitive Disorders

Ey, F. Menniti, F. Nelson, 2012 .

Inhibition of K+-stimulated [3H]dopamine and [14C]acetylcholine release by the putative dopamine autoreceptor agonist, B-HT 920

W. Lovenberg, C. J. Schmidt, A. Lobur, 1986, Naunyn-Schmiedeberg's Archives of Pharmacology.

Release of [3H]norepinephrine from rat hippocampal slices by N-methyl-D-aspartate: comparison of the inhibitory effects of Mg2+ and MK-801.

C. J. Schmidt, V. L. Taylor, 1988, European journal of pharmacology.

Assessment of adverse effects of neurotropic drugs in monkeys with the “Drug Effects on the Nervous System” (DENS) scale

F. Menniti, C. J. Schmidt, S. Papa, 2013, Journal of Neuroscience Methods.

A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of Schizophrenia.

E. Pickering, C. J. Schmidt, N. DeMartinis, 2019, Journal of clinical psychopharmacology.

Methamphetamine‐Induced Depression of Monoamine Synthesis in the Rat: Development of Tolerance

C. J. Schmidt, G. Hanson, J. Gibb, 1985, Journal of neurochemistry.

L‐Dopa Potentiates the Neurotoxicity of Some Amphetamine Analogues

C. J. Schmidt, 1992, Annals of the New York Academy of Sciences.

Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward

J. Kehne, C. J. Schmidt, R. Frank, 1995, Pharmacology Biochemistry and Behavior.

Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.

J. Pandit, W. Hoffman, M. Hajós, 2018, Journal of medicinal chemistry.

Blockade of Striatal 5‐Hydroxytryptmine2 Receptors Reduces the Increase in Extracellullar Concentrations of Dopamine Produced by the Amphhetamine analogue 3,4‐Methylenedioxymethamphetamine

C. J. Schmidt, C. Sullivan, G. M. Fedayal, 1994, Journal of neurochemistry.

Glycine transporter type 1 blockade changes NMDA receptor‐mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels

M. Martina, C. J. Schmidt, R. Bergeron, 2004, The Journal of physiology.

Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

Anne W. Schmidt, F. Menniti, F. Nelson, 2009, Journal of medicinal chemistry.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

Laura McDowell, Spiros Liras, Mihaly Hajos, 2012, Journal of medicinal chemistry.

1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis.

A. Ganong, F. Tingley, J. Siuciak, 2011, Journal of medicinal chemistry.

5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis.

C. J. Schmidt, T. Humphreys, S. Sorensen, 1992, The Journal of pharmacology and experimental therapeutics.

Guanine nucleotides are competitive inhibitors of N-methyl-D-aspartate at its receptor site both in vitro and in vivo.

C. J. Schmidt, I. Reynolds, B. M. Baron, 1989, The Journal of pharmacology and experimental therapeutics.

The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.

C. J. Schmidt, G. Fadayel, Christopher J. Schmidt, 1995, European journal of pharmacology.

Mechanisms of synaptic fatigue in a developing autonomic ganglion.

C. J. Schmidt, C. Bowers, 1992, Developmental biology.

Chloral hydrate anesthesia antagonizes the neurotoxicity of 3,4-methylenedioxymethamphetamine.

C. J. Schmidt, V. L. Taylor, C. K. Black, 1990, European journal of pharmacology.

Novel approaches for the treatment of schizophrenia

C. J. Schmidt, Bruce N. Rogers, 1999 .

In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659

B. Gulyás, J. Mulder, C. Halldin, 2019, Brain Research.

Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide

F. Menniti, C. J. Schmidt, J. Harms, 2019, Front. Neurosci..

Modulation of NMDA receptor function by inhibition of d-amino acid oxidase in rodent brain

A. Ganong, M. Hajós, P. Seymour, 2011, Neuropharmacology.

Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.

B. L. Kormos, C. J. Schmidt, Travis T Wager, 2017, ACS chemical neuroscience.

Evidence for specific methylenedioxymethamphetamine (ecstasy) binding sites in the rat brain.

W. Lovenberg, C. J. Schmidt, D. Gehlert, 1985, European journal of pharmacology.

PDE9A-mediated regulation of cGMP: Developing a biomarker for a novel therapy for Alzheimer's disease

F. Menniti, F. Tingley, D. Stephenson, 2009, Alzheimer's & Dementia.

Analysis of (R)-4-oxo-5-phosphononorvaline (MDL 100,453) in rat plasma and brain dialysate using liquid chromatography after derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate.

C. J. Schmidt, K. Haegele, B. M. Baron, 1995, Journal of pharmaceutical and biomedical analysis.